AN2 Therapeutics, Inc. · NASDAQ:ANTX
Commodore Capital LP reported a 9.90% stake in AN2 Therapeutics, Inc. (Schedule 13G/A)
Event Sep 30, 2026 · Filed Nov 16, 2026
Commodore Capital LP reported a 9.90% stake in AN2 Therapeutics, Inc., 3,879,705 shares, as a passive investor on Sep 30, 2026. Filed Nov 16, 2026 (Schedule 13G/A).
- Stake
- 9.90%
- Shares
- 3,879,705
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Commodore Capital LP | 9.90% | 3,879,705 |
| Commodore Capital Master LP | 9.90% | 3,879,705 |
| Robert Egen Atkinson | 9.90% | 3,879,705 |
| Michael Kramarz | 9.90% | 3,879,705 |
Source
Download original · View original at SEC
Related
- AN2 Therapeutics, Inc.
- Commodore Capital LP
- AN2 Therapeutics, Inc. shareholders
- Schedule 13G · Commodore Capital LP · Mar 16, 2026
- Schedule 13G/A · Eric Easom · Nov 13, 2026
- Schedule 13G/A · Coastlands Capital LP · Nov 13, 2026
- Form 4 · Eizen Joshua M · Nov 6, 2026
- Form 4 · Aziz Kabeer · Oct 13, 2026
- Form 4 · Martin Patricia A. · Oct 13, 2026